Low-Dose Naltrexone for Adults 65+: School, Work, and Activity Considerations

Is there any geriatric-specific evidence for LDN?

Low-dose naltrexone means naltrexone at 0.5 to 6 mg a day, most often 4.5 mg, used off-label and supplied mainly through compounding pharmacies [1]. No LDN product or LDN indication is FDA-approved [1][8], and FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [9]. The FDA-approved 50 mg tablets are indicated for the treatment of alcohol dependence and for blockade of the effects of exogenously administered opioids; the FDA-approved 380 mg Vivitrol injection is indicated for alcohol dependence and for prevention of relapse to opioid dependence following opioid detoxification [2][3]. Both labels were written for those doses and give no guidance on LDN doses [2][3][1].

The only label statement aimed at older adults is in the Vivitrol label: no patients over 65 were included in its studies of opioid-dependent patients, the pharmacokinetics of the 380 mg gluteal injection have not been evaluated in the geriatric population, and because the drug is substantially excreted by the kidney, monitoring renal function may be useful [3]. That is the monthly injection, not a compounded capsule.

Can LDN make exercise and daily activity easier?

The evidence is mixed and has weakened as trials got larger. A 2013 crossover trial of 31 women with fibromyalgia found daily pain fell 28.8% on 4.5 mg versus 18.0% on placebo (P=0.016), while fatigue and sleep did not improve [10]. Larger placebo-controlled trials did not confirm a pain benefit: 99 women on 6 mg had a between-group pain difference of -0.34 points (95% CI -0.95 to 0.27, p=0.27) [5], and 98 women followed for 12 months had an adjusted difference of 0.49 points (p=0.236) at 3 months, with secondary outcomes, including functional impairment and disability, showing minor, inconsistent changes [6]. A 58-patient crossover trial of 4.5 mg found no significant difference from placebo on its FIQR or pain-rating outcomes [11]. A meta-analysis of 4 trials and 222 patients found a small reduction in pain scores (mean difference -0.86, 95% CI -1.20 to -0.51) but no significant difference on the Fibromyalgia Impact Questionnaire [4].

For daily functioning, a systematic review searched to May 2026 found no randomized trials of LDN in long COVID. Four uncontrolled before-and-after studies (n=155; LDN 1 to 6 mg a day) reported improved daily functioning (Hedges g -0.93), but uncontrolled data cannot show a benefit over placebo [13].

Sleep, alertness and opioid pain medicines

LDN trials report mostly mild, transient effects, most often insomnia, vivid dreams, nausea and dizziness [1], and a 2024 meta-analysis found more vivid dreams and nausea with LDN than with placebo [4]. Full-dose figures give direction only: with the 380 mg injection, dizziness or syncope occurred in 13% versus 4% on placebo and insomnia in 14% versus 12% [3].

Naltrexone is contraindicated in anyone receiving opioid analgesics, anyone currently dependent on opioids including methadone or buprenorphine, anyone in acute opioid withdrawal, anyone with a positive urine screen for opioids, and anyone who has failed a naloxone challenge test [2][3]. Patients taking naltrexone may not benefit from opioid-containing cough and cold preparations, antidiarrheal preparations or opioid analgesics [2]. If opioid analgesia is needed in an emergency during tablet therapy, the tablet label says the amount required may be greater than usual and the resulting respiratory depression may be deeper and more prolonged [2]. The Vivitrol label suggests regional analgesia or non-opioid analgesics when pain relief is needed during its blockade [3]. Both labels advise strongly considering an opioid overdose reversal agent such as naloxone or nalmefene when treatment starts and at each renewal or injection [2][3].